Urology Times

Sunday Spotlight 🌟: In this video, Suzanne B. Merrill, MD, of Colorado Urology, discusses the ImmunityBio, Inc. expanded access program for recombinant BCG that was recently authorized by the FDA. For more 🔗 : https://lnkd.in/gWSuSdXz

🚨 BREAKING: The #FDA has approved perioperative durvalumab in combination with neoadjuvant chemotherapy for adult patients with muscle-invasive bladder cancer (#MIBC). The approval is supported by data from the phase 3 #NIAGARA trial, in which the durvalumab/chemotherapy combination extended event-free survival and overall survival vs neoadjuvant chemotherapy alone. 🔗 Learn more about the data supporting the decision here: https://lnkd.in/gBpueQ36 #BLCSM

🚨 BREAKING: The FDA has approved an expanded indication for 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto) to include use in the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer (#mCRPC) in the pre-chemotherapy setting. The approval is supported by results from the PSMAfore trial, which showed that 177Lu-PSMA-617 prolonged radiographic progression-free survival compared with a change in ARPI in this patient population. For more 🔗 : https://lnkd.in/ecUCusAC

Article of the Week: Andrea Necchi, MD, shares in-depth insights into the study, “Perioperative outcomes of neoadjuvant (neoadj) TAR-200 plus cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC) ineligible for or refusing neoadj cisplatin-based chemotherapy (NAC),” which was presented at the 40th Annual European Association of Urology (EAU) Congress in Madrid, Spain. 🔗 : https://lnkd.in/gYRYmBAS

The NeuroSAFE technique showed value as a adjunct tool to guide nerve-sparing during robot-assisted radical prostatectomy (#RARP), according to findings from the phase 3 NeuroSAFE PROOF trial presented at #EAU25. Overall, data showed that NeuroSAFE RARP led to improved erectile function at 12 months and improved urinary continence at 3 months compared with standard RARP. According to author Greg Shaw, this technique may be most valuable for younger patients who wouldn't typically be offered nerve-sparing surgery. Read more on the findings 🔗 : https://lnkd.in/eRTsNA3J

At #EAU25, Trinity Bivalacqua, MD, of University of Pennsylvania Perelman School of Medicine presented translational data on cretostimogene grenadenorepvec, an investigational agent for BCG-unresponsive NMIBC. Overall, the additional results from BOND-003 showed: ▪️ Cretostimogene was well-tolerated, with the majority of AEs being grade 1-2 ▪️ Sustained local activity for 4-5 days ▪️ Stable and robust antibody and anti-tumor response ▪️ No need for post-cretostimogene close contact precautions For more 🔗 :https://lnkd.in/efCrxZDA

Data presented at #EAU25 showed that bel-sar, an investigational virus-like drug conjugate, had favorable safety and efficacy in patients with #NMIBC. In patients with intermediate-risk disease, 4 of 5 patients achieved a complete response. The therapy was also well-tolerated. Aura Biosciences next plans to initiate a trial to assess the therapeutic ahead of or in place of TURBT across different risk categories. According to presenting author Seth Lerner, MD, bel-sar shows potential to become a novel treatment approach in bladder cancer. For more 🔗 : https://lnkd.in/e3_FGeJE #blcsm

🤔 Are you a urologist who treats patients with bladder cancer? If so, we want to hear from you! We invite you to fill out a brief survey on treatment patterns and preferences in non­–muscle-invasive bladder cancer, developed by Urology Times Co-Editor in Chief Michael S. Cookson, MD, MMHC, FACS. 🔗 : https://lnkd.in/ekhWuuyi

🚨 BREAKING: The #FDA has approved gepotidacin for female adult and pediatric patients with uncomplicated urinary tract infection (#UTI) caused by select susceptible microorganisms. The approval is backed by data from the phase 3 EAGLE-2 and EAGLE-3 trials, in which gepotidacin demonstrated non-inferiority and superiority, respectively, to nitrofurantoin. According to GSK, commercial launch in the US is planned for the second half of 2025. Read more 🔗 : https://lnkd.in/e-9YVXHX #uUTI #urology

WATER III trial at #EAU25: Compared Aquablation to transurethral laser enucleation of large prostates (LEP) Data showed: ▪️ Aquablation and LEP were comparable in short-term symptom improvement ▪️ Aquablation showed lower rates of ejaculatory dysfunction and stress urinary incontinence ▪️ LEP demonstrated greater improvements in prostate volume reduction and urinary flow rate According to Naeem Bhojani of Université de Montréal, these findings highlight the effectiveness of Aquablation for #BPH treatment. For more: https://lnkd.in/eYarW6qK